결핵균 치료 시장 : 제품 유형별, 최종사용자별, 지역별 - 세계 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2032년)
Mycobacterium Tuberculosis Treatment Market by Product Type, End-Users, and Geography (North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa): Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032
상품코드
:
1477979
리서치사
:
Persistence Market Research
발행일
:
2024년 05월
페이지 정보
:
영문 287 Pages
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
샘플 요청 목록에 추가
Persistence Market Research의 결핵균 치료 시장 조사 보고서에서는 2024-2032년 시장 동향, 성장 촉진요인·과제, 향후기술 혁신을 상세 분석하고 있습니다. 시장의 현황과 예측에 관한 인사이트를 제공합니다.
세계의 결핵균 치료제 시장은 2024년 21억 3,000만 달러에서 2032년에는 24억 달러로, CAGR 1.2%를 달성할 것으로 예측됩니다.
주요 인사이트
추정 시장 규모(2024년) : 21억 3,000만 달러
예측 시장 규모(2032년) : 24억 달러
세계 시장 성장률(CAGR 2024-2032년) : 1.2%
결핵균 치료 시장 - 리포트 범위 :
결핵균은 결핵을 유발하는 박테리아로 주로 폐를 침범하지만 다른 장기에도 침입할 수 있습니다. 이 보고서는 전 세계 결핵 환자 증가, 결핵 연구 자금 지원 증가, 진단 기술 강화 등 결핵균 치료에 대한 수요를 촉진하는 요인에 초점을 맞추었습니다.
시장 성장 촉진요인 :
결핵 치료제에 대한 수요는 여러 가지 요인에 의해 증가하고 있습니다. 전 세계 결핵 환자 증가, 검진 및 진단 수단 강화, 보다 신속하고 효과적인 약물 요법 개발 등이 이러한 성장의 원동력이 되고 있습니다. 약제 내성 결핵 증가는 병용요법이나 장기적인 백신 전략과 같은 새로운 치료 접근법에 대한 연구를 촉진하고 있습니다. 또한 세계 보건 활동과 결핵 프로그램에 대한 자금 지원은 시장 확대에 크게 기여하고 있습니다.
시장 성장 억제요인 :
결핵균 치료 시장은 첨단 결핵균 치료제의 높은 비용, 저소득 국가의 제한된 의료 시설 접근성, 높은 치료 불이동률 등의 문제에 직면해 있습니다. 약제 내성 결핵 관리의 복잡성과 긴 치료 기간도 시장 성장을 저해하는 요인으로 작용하고 있습니다. 복잡한 규제와 국가마다 다른 정부 정책으로 인해 새로운 치료법의 도입이 지연될 수 있습니다.
시장 기회 :
결핵균 치료제 시장에는 큰 혁신의 기회가 존재합니다. 분자생물학과 유전공학의 발전은 약제 내성 결핵균에 대한 보다 효과적인 새로운 치료법을 개발할 수 있는 가능성을 제공합니다. 공공-민간 파트너십과 국제 협력은 연구개발 노력을 가속화하는 한편, 공중보건 캠페인을 강화하여 인지도를 높이고 조기 발견과 치료 프로토콜 준수를 향상시킬 수 있습니다.
이 보고서에서 다룬 주요 질문
2024-2032년 결핵균 치료제 시장의 예상 CAGR은?
결핵균 치료제 시장의 성장을 가속하는 주요 요인은 무엇인가?
가장 큰 시장 점유율을 차지하는 치료 방식은 무엇인가?
세계 결핵균 치료제 시장의 주요 기업은?
주요 기업은 어떤 전략을 통해 경쟁에서 살아남기 위해 어떤 전략을 채택하고 있는가?
목차 제1장 주요 요약
제2장 시장 개요
시장 범위/분류
시장의 정의/범위/제한
포함과 제외
제3장 주요 시장 동향
시장에 영향을 미치는 주요 동향
제품 혁신/개발 동향
제4장 주요 성공요인
지역별 질병 역학
규제 시나리오
PESTLE 분석
Porter의 산업 분석
제조업체별 주요 프로모션 전략
공급망 분석
제5장 시장 배경
거시경제 요인
예측 요인 - 관련성과 영향
시장 역학
제6장 COVID-19 위기 분석
COVID-19와 영향 분석
질환별 매출
치료 유형별 매출
투여 경로별 매출
유통 채널별 매출
국가별 매출
2024년 시장 시나리오
제7장 세계의 결핵균 치료 시장의 수요 분석
과거 시장 가치 분석(2019-2023년)
현재 및 향후 시장 가치 예측(2024-2032년)
제8장 세계의 결핵균 치료 시장 분석 : 질환별
서론/주요 조사 결과
과거 시장 규모 분석 : 질환별(2019-2023년)
현재 및 향후 시장 규모 분석과 예측 : 질환별(2024-2032년)
질환별 시장의 매력 분석
제9장 세계의 결핵균 치료 시장 분석 : 치료 유형별
서론/주요 조사 결과
과거 시장 규모 분석 : 치료 유형별(2019-2023년)
현재 및 향후 시장 규모 분석과 예측 : 치료 유형별(2024-2032년)
치료 유형별 시장의 매력 분석
제10장 세계의 결핵균 치료 시장 분석 : 투여 경로별
서론/주요 조사 결과
과거 시장 규모 분석 : 투여 경로별(2019-2023년)
현재 및 향후 시장 규모 분석과 예측 : 투여 경로별(2024-2032년)
투여 경로별 시장의 매력 분석
제11장 세계의 결핵균 치료 시장 분석 : 유통 채널별
서론/주요 조사 결과
과거 시장 규모 분석 : 유통 채널별(2019-2023년)
현재 및 향후 시장 규모 분석과 예측 : 유통 채널별(2024-2032년)
병원 약국
온라인 약국
소매 약국
법인 및 개인용 판매
유통 채널별 시장의 매력 분석
제12장 세계의 결핵균 치료 시장 분석 : 지역별
서론
과거 시장 규모 분석 : 지역별(2019-2023년)
현재 및 향후 시장 규모 분석과 예측 : 지역별(2024-2032년)
북미
라틴아메리카
유럽
동아시아
남아시아
오세아니아
중동 및 아프리카
지역별 시장의 매력 분석
제13장 북미의 결핵균 치료 시장 분석
제14장 라틴아메리카의 결핵균 치료 시장 분석
제15장 유럽의 결핵균 치료 시장 분석
제16장 남아시아의 결핵균 치료 시장 분석
제17장 동아시아의 결핵균 치료 시장 분석
제18장 오세아니아의 결핵균 치료 시장 분석
제19장 중동 및 아프리카의 결핵균 치료 시장 분석
제20장 시장 구조 분석
기업 계층별 시장 분석
주요 기업의 시장 점유율 분석
시장 입지 분석
제21장 경쟁 분석
경쟁 대시보드
경쟁 벤치마킹
경쟁의 상세
AstraZeneca
Johnson &Johnson Private Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Mylan NV
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Allergan
Merck &Co., Inc.
Pfizer Inc.
GlaxoSmithKline plc
Hikma Pharmaceuticals PLC
Cipla Inc.
Endo International plc
Otsuka Pharmaceutical Co., Ltd.
STI Pharma, LLC
제22장 전제와 두자어
제23장 조사 방법
KSA
영문 목차
The Mycobacterium Tuberculosis Treatment Market report by Persistence Market Research provides an in-depth analysis of the market trends, growth drivers, challenges, and prospective innovations spanning from 2024 to 2032. It offers insights into the current landscape and future projections of the market.
The global market for Mycobacterium tuberculosis treatment is expected to achieve a compound annual growth rate (CAGR) of 1.2% from USD 2.13 billion in 2024 to USD 2.40 billion by 2032.
Key Insights:
Estimated Market Size (2024): USD 2.13 Billion
Projected Market Size (2032): USD 2.40 Billion
Global Market Growth Rate (CAGR 2024 to 2032): 1.2%
Mycobacterium Tuberculosis Treatment Market - Report Scope:
Mycobacterium tuberculosis is the bacterium that causes tuberculosis (TB), primarily affecting the lungs but can invade other organs. This report focuses on the drivers promoting the demand for TB treatment, including the global rise in TB cases, increased funding for TB research, and enhancements in diagnostic technologies.
Market Growth Drivers:
The demand for TB treatment is escalating due to several factors. The increase in TB cases globally, enhanced screening and diagnostic measures, and the development of faster-acting and more effective drug regimens drive this growth. The rise of drug-resistant TB forms has spurred research into novel treatment approaches, including combination therapies and longer-term vaccine strategies. Additionally, global health initiatives and funding for TB programs significantly propel market expansion.
Market Restraints:
The Mycobacterium Tuberculosis Treatment Market faces challenges such as the high cost of advanced TB drugs, limited access to medical facilities in low-income countries, and significant rates of treatment non-compliance. The complexity of managing drug-resistant TB and the long duration of treatment also hinder market growth. Regulatory complexities and varying government policies across countries can delay the introduction of new treatments.
Market Opportunities:
Significant opportunities exist for innovation within the TB treatment market. Advances in molecular biology and genetic engineering offer potential for developing new treatments that are more effective against drug-resistant strains of TB. Public-private partnerships and international collaborations can accelerate research and development efforts, while increasing public health campaigns can raise awareness and improve early detection and compliance with treatment protocols.
Key Questions Addressed in the Report:
What is the Expected CAGR of the Mycobacterium Tuberculosis Treatment Market from 2024 to 2032?
What are the Key Factors Driving the Growth of the Mycobacterium Tuberculosis Treatment Market?
Which Treatment Modality Holds the Largest Market Share?
Who are the Key Players in the Global Mycobacterium Tuberculosis Treatment Market?
What Strategies are Adopted by Leading Companies to Remain Competitive?
Competitive Landscape and Business Strategies:
Key players in the market include Johnson & Johnson, Sanofi, Bayer AG, and GlaxoSmithKline plc. These companies focus on innovations in TB treatment, market penetration in untapped regions, and forming strategic partnerships to stay competitive. For instance, Johnson & Johnson offers Sirturo for multi-drug resistant TB, and Sanofi has been involved in developing booster combinations to enhance treatment efficacy.
Key Companies Profiled:
AstraZeneca
Johnson & Johnson Private Limited
Eli Lilly and Company
F. Hoffmann-La Roche Ltd.
Mylan N.V.
Teva Pharmaceutical Industries Ltd.
Sanofi
Novartis AG
Sun Pharmaceutical Industries Ltd.
Aurobindo Pharma
Lupin
Allergan
Merck & Co., Inc.
Pfizer Inc.
GlaxoSmithKline plc
Hikma Pharmaceuticals PLC
Cipla Inc.
Endo International plc
Otsuka Pharmaceutical Co., Ltd.
STI Pharma, LLC
Mycobacterium Tuberculosis Treatment Market Segmentation:
By Disease Type:
By Treatment Type:
First-Line of Drugs
Second-Line of Drugs
By Route of Administration:
Oral
Intravenous
Intramuscular
By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Institutional and Retail Sales
By Region:
North America
Latin America
Europe
South Asia
East Asia
Oceania
Middle East & Africa
Table of Contents 1. Executive Summary
1.1. Global Market Outlook
1.2. Demand Side Trends
1.3. Supply-Side Trends
1.4. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
2.3. Inclusions & Exclusions
3. Key Market Trends
3.1. Key Trends Impacting the Market
3.2. Product Innovation / Development Trends
4. Key Success Factors
4.1. Disease Epidemiology, By Region
4.2. Regulatory Scenario
4.3. PESTLE Analysis
4.4. Porter's Analysis
4.5. Key Promotional Strategies, by Manufacturers
4.6. Supply Chain Analysis
5. Market Background
5.1. Macro-Economic Factors
5.1.1. Global GDP Growth Outlook
5.1.2. Global Healthcare Expenditure
5.1.3. Global Infectious Disease Treatment Market
5.2. Forecast Factors - Relevance & Impact
5.2.1. Growing Burden of Tuberculosis Disease
5.2.2. Increasing Research and Development Activities
5.2.3. Adoption of Different Treatments for Infectious Disease
5.2.4. Rising Government Support
5.2.5. Increasing FDA Approvals of New Drugs
5.2.6. Strategic Mergers and Acquisitions Among Local Manufacturers
5.3. Market Dynamics
5.3.1. Drivers
5.3.2. Restraints
5.3.3. Opportunity Analysis
6. COVID-19 Crisis Analysis
6.1. COVID-19 and Impact Analysis
6.1.1. Revenue By Disease Type
6.1.2. Revenue By Treatment Type
6.1.3. Revenue By Route of Administration
6.1.4. Revenue By Distribution Channel
6.1.5. Revenue By Country
6.2. 2024 Market Scenario
7. Global Mycobacterium Tuberculosis Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2032
7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2032
7.2.1. Y-o-Y Growth Trend Analysis
7.2.2. Absolute $ Opportunity Analysis
8. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Disease Type
8.1. Introduction / Key Findings
8.2. Historical Market Size (US$ Mn) Analysis By Disease Type, 2019-2023
8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2024-2032
8.3.1. Latent TB
8.3.2. Active TB
8.4. Market Attractiveness Analysis By Disease Type
9. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Treatment Type
9.1. Introduction / Key Findings
9.2. Historical Market Size (US$ Mn) Analysis By Treatment Type, 2019-2023
9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Treatment Type, 2024-2032
9.3.1. First-Line of Drugs
9.3.2. Second-Line of Drugs
9.4. Market Attractiveness Analysis By Treatment Type
10. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration
10.1. Introduction / Key Findings
10.2. Historical Market Size (US$ Mn) Analysis By Route of Administration, 2019-2023
10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2032
10.3.1. Oral
10.3.2. Intravenous
10.3.3. Intramuscular
10.4. Market Attractiveness Analysis By Route of Administration
11. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel
11.1. Introduction / Key Findings
11.2. Historical Market Size (US$ Mn) Analysis By Distribution Channel, 2019-2023
11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2032
11.3.1. Hospital Pharmacies
11.3.2. Online Pharmacies
11.3.3. Retail Pharmacies
11.3.4. Institutional and Retail Sales
11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032, by Region
12.1. Introduction
12.2. Historical Market Size (US$ Mn) Analysis, By Region, 2019-2023
12.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Region, 2024-2032
12.3.1. North America
12.3.2. Latin America
12.3.3. Europe
12.3.4. East Asia
12.3.5. South Asia
12.3.6. Oceania
12.3.7. Middle East and Africa (MEA)
12.4. Market Attractiveness Analysis By Region
13. North America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032
13.1. Introduction
13.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
13.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
13.3.1. By Country
13.3.1.1. U.S.
13.3.1.2. Canada
13.3.2. By Disease Type
13.3.3. By Treatment Type
13.3.4. By Route of Administration
13.3.5. By Distribution Channel
13.4. Market Attractiveness Analysis
13.4.1. By Country
13.4.2. By Disease Type
13.4.3. By Treatment Type
13.4.4. By Route of Administration
13.4.5. By Distribution Channel
13.5. Market Trends
13.6. Key Market Participants - Intensity Mapping
13.7. Drivers and Restraints - Impact Analysis
13.8. Country Level Analysis & Forecast
13.8.1. U.S. Mycobacterium Tuberculosis Treatment Market Analysis
13.8.1.1. Introduction
13.8.1.2. Market Analysis and Forecast by Market Taxonomy
13.8.1.2.1. By Disease Type
13.8.1.2.2. By Treatment Type
13.8.1.2.3. By Route of Administration
13.8.1.2.4. By Distribution Channel
13.8.2. Canada Mycobacterium Tuberculosis Treatment Market Analysis
13.8.2.1. Introduction
13.8.2.2. Market Analysis and Forecast by Market Taxonomy
13.8.2.2.1. By Disease Type
13.8.2.2.2. By Treatment Type
13.8.2.2.3. By Route of Administration
13.8.2.2.4. By Distribution Channel
14. Latin America Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032
14.1. Introduction
14.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
14.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
14.3.1. By Country
14.3.1.1. Brazil
14.3.1.2. Mexico
14.3.1.3. Rest of Latin America
14.3.2. By Disease Type
14.3.3. By Treatment Type
14.3.4. By Route of Administration
14.3.5. By Distribution Channel
14.4. Market Attractiveness Analysis
14.4.1. By Country
14.4.2. By Disease Type
14.4.3. By Treatment Type
14.4.4. By Route of Administration
14.4.5. By Distribution Channel
14.5. Market Trends
14.6. Key Market Participants - Intensity Mapping
14.7. Drivers and Restraints - Impact Analysis
14.8. Country Level Analysis & Forecast
14.8.1. Brazil Mycobacterium Tuberculosis Treatment Market Analysis
14.8.1.1. Introduction
14.8.1.2. Market Analysis and Forecast by Market Taxonomy
14.8.1.2.1. By Disease Type
14.8.1.2.2. By Treatment Type
14.8.1.2.3. By Route of Administration
14.8.1.2.4. By Distribution Channel
14.8.2. Argentina Mycobacterium Tuberculosis Treatment Market Analysis
14.8.2.1. Introduction
14.8.2.2. Market Analysis and Forecast by Market Taxonomy
14.8.2.2.1. By Disease Type
14.8.2.2.2. By Treatment Type
14.8.2.2.3. By Route of Administration
14.8.2.2.4. Distribution Channel
14.8.3. Mexico Mycobacterium Tuberculosis Treatment Market Analysis
14.8.3.1. Introduction
14.8.3.2. Market Analysis and Forecast by Market Taxonomy
14.8.3.2.1. By Disease Type
14.8.3.2.2. By Treatment Type
14.8.3.2.3. By Route of Administration
14.8.3.2.4. By Distribution Channel
15. Europe Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032
15.1. Introduction
15.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
15.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
15.3.1. By Country
15.3.1.1. Germany
15.3.1.2. Italy
15.3.1.3. France
15.3.1.4. U.K.
15.3.1.5. Spain
15.3.1.6. BENELUX
15.3.1.7. Nordic Countries
15.3.1.8. Russia
15.3.1.9. Rest of Europe
15.3.2. By Disease Type
15.3.3. By Treatment Type
15.3.4. By Route of Administration
15.3.5. By Distribution Channel
15.4. Market Attractiveness Analysis
15.4.1. By Country
15.4.2. By Disease Type
15.4.3. By Treatment Type
15.4.4. By Route of Administration
15.4.5. By Distribution Channel
15.5. Market Trends
15.6. Key Market Participants - Intensity Mapping
15.7. Drivers and Restraints - Impact Analysis
15.8. Country Level Analysis & Forecast
15.8.1. Germany Mycobacterium Tuberculosis Treatment Market Analysis
15.8.1.1. Introduction
15.8.1.2. Market Analysis and Forecast by Market Taxonomy
15.8.1.2.1. By Disease Type
15.8.1.2.2. By Treatment Type
15.8.1.2.3. By Route of Administration
15.8.1.2.4. By Distribution Channel
15.8.2. France Mycobacterium Tuberculosis Treatment Market Analysis
15.8.2.1. Introduction
15.8.2.2. Market Analysis and Forecast by Market Taxonomy
15.8.2.2.1. By Disease Type
15.8.2.2.2. By Treatment Type
15.8.2.2.3. By Route of Administration
15.8.2.2.4. By Distribution Channel
15.8.3. Italy Mycobacterium Tuberculosis Treatment Market Analysis
15.8.3.1. Introduction
15.8.3.2. Market Analysis and Forecast by Market Taxonomy
15.8.3.2.1. By Disease Type
15.8.3.2.2. By Treatment Type
15.8.3.2.3. By Route of Administration
15.8.3.2.4. By Distribution Channel
15.8.4. Spain Mycobacterium Tuberculosis Treatment Market Analysis
15.8.4.1. Introduction
15.8.4.2. Market Analysis and Forecast by Market Taxonomy
15.8.4.2.1. By Disease Type
15.8.4.2.2. By Treatment Type
15.8.4.2.3. By Route of Administration
15.8.4.2.4. By Distribution Channel
15.8.5. U.K. Mycobacterium Tuberculosis Treatment Market Analysis
15.8.5.1. Introduction
15.8.5.2. Market Analysis and Forecast by Market Taxonomy
15.8.5.2.1. By Disease Type
15.8.5.2.2. By Treatment Type
15.8.5.2.3. By Route of Administration
15.8.5.2.4. By Distribution Channel
15.8.6. Benelux Union Mycobacterium Tuberculosis Treatment Market Analysis
15.8.6.1. Introduction
15.8.6.2. Market Analysis and Forecast by Market Taxonomy
15.8.6.2.1. By Disease Type
15.8.6.2.2. By Treatment Type
15.8.6.2.3. By Route of Administration
15.8.6.2.4. By Distribution Channel
15.8.7. Nordic Countries Mycobacterium Tuberculosis Treatment Market Analysis
15.8.7.1. Introduction
15.8.7.2. Market Analysis and Forecast by Market Taxonomy
15.8.7.2.1. By Disease Type
15.8.7.2.2. By Treatment Type
15.8.7.2.3. By Route of Administration
15.8.7.2.4. By Distribution Channel
15.8.8. Russia Mycobacterium Tuberculosis Treatment Market Analysis
15.8.8.1. Introduction
15.8.8.2. Market Analysis and Forecast by Market Taxonomy
15.8.8.2.1. By Disease Type
15.8.8.2.2. By Treatment Type
15.8.8.2.3. By Route of Administration
15.8.8.2.4. By Distribution Channel
16. South Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032
16.1. Introduction
16.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
16.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
16.3.1. By Country
16.3.1.1. India
16.3.1.2. Thailand
16.3.1.3. Indonesia
16.3.1.4. Malaysia
16.3.1.5. Rest of South Asia
16.3.2. By Disease Type
16.3.3. By Treatment Type
16.3.4. By Route of Administration
16.3.5. By Distribution Channel
16.4. Market Attractiveness Analysis
16.4.1. By Country
16.4.2. By Disease Type
16.4.3. By Treatment Type
16.4.4. By Route of Administration
16.4.5. By Distribution Channel
16.5. Market Trends
16.6. Key Market Participants - Intensity Mapping
16.7. Drivers and Restraints - Impact Analysis
16.8. Country Level Analysis & Forecast
16.8.1. India Mycobacterium Tuberculosis Treatment Market Analysis
16.8.1.1. Introduction
16.8.1.2. Market Analysis and Forecast by Market Taxonomy
16.8.1.2.1. By Disease Type
16.8.1.2.2. By Treatment Type
16.8.1.2.3. By Route of Administration
16.8.1.2.4. By Distribution Channel
16.8.2. Indonesia Mycobacterium Tuberculosis Treatment Market Analysis
16.8.2.1. Introduction
16.8.2.2. Market Analysis and Forecast by Market Taxonomy
16.8.2.2.1. By Disease Type
16.8.2.2.2. By Treatment Type
16.8.2.2.3. By Route of Administration
16.8.2.2.4. By Distribution Channel
16.8.3. Malaysia Mycobacterium Tuberculosis Treatment Market Analysis
16.8.3.1. Introduction
16.8.3.2. Market Analysis and Forecast by Market Taxonomy
16.8.3.2.1. By Disease Type
16.8.3.2.2. By Treatment Type
16.8.3.2.3. By Route of Administration
16.8.3.2.4. By Distribution Channel
16.8.3.2.5. By Distribution Channel
16.8.4. Thailand Mycobacterium Tuberculosis Treatment Market Analysis
16.8.4.1. Introduction
16.8.4.2. Market Analysis and Forecast by Market Taxonomy
16.8.4.2.1. By Disease Type
16.8.4.2.2. By Treatment Type
16.8.4.2.3. By Route of Administration
16.8.4.2.4. By Distribution Channel
17. East Asia Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032
17.1. Introduction
17.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
17.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
17.3.1. By Country
17.3.1.1. China
17.3.1.2. Japan
17.3.1.3. South Korea
17.3.2. By Disease Type
17.3.3. By Treatment Type
17.3.4. By Route of Administration
17.3.5. By Distribution Channel
17.4. Market Attractiveness Analysis
17.4.1. By Country
17.4.2. By Disease Type
17.4.3. By Treatment Type
17.4.4. By Route of Administration
17.4.5. By Distribution Channel
17.5. Market Trends
17.6. Key Market Participants - Intensity Mapping
17.7. Drivers and Restraints - Impact Analysis
17.8. Country Level Analysis & Forecast
17.8.1. China Mycobacterium Tuberculosis Treatment Market Analysis
17.8.1.1. Introduction
17.8.1.2. Market Analysis and Forecast by Market Taxonomy
17.8.1.2.1. By Disease Type
17.8.1.2.2. By Treatment Type
17.8.1.2.3. By Route of Administration
17.8.1.2.4. By Distribution Channel
17.8.2. Japan Mycobacterium Tuberculosis Treatment Market Analysis
17.8.2.1. Introduction
17.8.2.2. Market Analysis and Forecast by Market Taxonomy
17.8.2.2.1. By Disease Type
17.8.2.2.2. By Treatment Type
17.8.2.2.3. By Route of Administration
17.8.2.2.4. By Distribution Channel
17.8.3. South Korea Mycobacterium Tuberculosis Treatment Market Analysis
17.8.3.1. Introduction
17.8.3.2. Market Analysis and Forecast by Market Taxonomy
17.8.3.2.1. By Disease Type
17.8.3.2.2. By Treatment Type
17.8.3.2.3. By Route of Administration
17.8.3.2.4. By Distribution Channel
18. Oceania Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032
18.1. Introduction
18.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
18.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
18.3.1. By Country
18.3.1.1. Australia
18.3.1.2. New Zealand
18.3.2. By Disease Type
18.3.3. By Treatment Type
18.3.4. By Route of Administration
18.3.5. By Distribution Channel
18.4. Market Attractiveness Analysis
18.4.1. By Country
18.4.2. By Disease Type
18.4.3. By Treatment Type
18.4.4. By Route of Administration
18.4.5. By Distribution Channel
18.5. Market Trends
18.6. Key Market Participants - Intensity Mapping
18.7. Drivers and Restraints - Impact Analysis
18.8. Country Level Analysis & Forecast
18.8.1. Australia Mycobacterium Tuberculosis Treatment Market Analysis
18.8.1.1. Introduction
18.8.1.2. Market Analysis and Forecast by Market Taxonomy
18.8.1.2.1. By Disease Type
18.8.1.2.2. By Treatment Type
18.8.1.2.3. By Route of Administration
18.8.1.2.4. By Distribution Channel
18.8.2. New Zealand Mycobacterium Tuberculosis Treatment Market Analysis
18.8.2.1. Introduction
18.8.2.2. Market Analysis and Forecast by Market Taxonomy
18.8.2.2.1. By Disease Type
18.8.2.2.2. By Treatment Type
18.8.2.2.3. By Route of Administration
18.8.2.2.4. By Distribution Channel
19. Middle East and Africa (MEA) Mycobacterium Tuberculosis Treatment Market Analysis 2019-2023 and Forecast 2024-2032
19.1. Introduction
19.2. Historical Market Size (US$ Mn) Analysis By Market Taxonomy, 2019-2023
19.3. Current and Future Market Size (US$ Mn) Analysis and Forecast, By Market Taxonomy, 2024-2032
19.3.1. By Country
19.3.1.1. GCC Countries
19.3.1.2. Turkey
19.3.1.3. North Africa
19.3.1.4. South Africa
19.3.1.5. Rest of Middle East and Africa
19.3.2. By Disease Type
19.3.3. By Treatment Type
19.3.4. By Route of Administration
19.3.5. By Distribution Channel
19.4. Market Attractiveness Analysis
19.4.1. By Country
19.4.2. By Disease Type
19.4.3. By Treatment Type
19.4.4. By Route of Administration
19.4.5. By Distribution Channel
19.5. Market Trends
19.6. Key Market Participants - Intensity Mapping
19.7. Drivers and Restraints - Impact Analysis
19.8. Country Level Analysis & Forecast
19.8.1. GCC Countries Mycobacterium Tuberculosis Treatment Market Analysis
19.8.1.1. Introduction
19.8.1.2. Market Analysis and Forecast by Market Taxonomy
19.8.1.2.1. By Disease Type
19.8.1.2.2. By Treatment Type
19.8.1.2.3. By Route of Administration
19.8.1.2.4. By Distribution Channel
19.8.2. Turkey Mycobacterium Tuberculosis Treatment Market Analysis
19.8.2.1. Introduction
19.8.2.2. Market Analysis and Forecast by Market Taxonomy
19.8.2.2.1. By Disease Type
19.8.2.2.2. By Treatment Type
19.8.2.2.3. By Route of Administration
19.8.2.2.4. By Distribution Channel
19.8.3. North Africa Mycobacterium Tuberculosis Treatment Market Analysis
19.8.3.1. Introduction
19.8.3.2. Market Analysis and Forecast by Market Taxonomy
19.8.3.2.1. By Disease Type
19.8.3.2.2. By Treatment Type
19.8.3.2.3. By Route of Administration
19.8.3.2.4. By Distribution Channel
19.8.4. South Africa Mycobacterium Tuberculosis Treatment Market Analysis
19.8.4.1. Introduction
19.8.4.2. Market Analysis and Forecast by Market Taxonomy
19.8.4.2.1. By Disease Type
19.8.4.2.2. By Treatment Type
19.8.4.2.3. By Route of Administration
19.8.4.2.4. By Distribution Channel
20. Market Structure Analysis
20.1. Market Analysis by Tier of Companies
20.2. Market Share Analysis of Top Players
20.3. Market Presence Analysis
20.3.1. Regional Footprint Analysis
20.3.2. Channel Footprint Analysis
21. Competition Analysis
21.1. Competition Dashboard
21.2. Competition Benchmarking
21.3. Competition Deep Dive
21.3.1. AstraZeneca
21.3.1.1. Overview
21.3.1.2. Product Portfolio
21.3.1.3. Key Financials
21.3.1.4. SWOT Analysis
21.3.1.5. Sales Footprint
21.3.1.6. Strategy Overview
21.3.1.7. Key Developments
21.3.1.7.1. Marketing Strategies
21.3.1.7.2. Channel Strategies
21.3.2. Johnson & Johnson Private Limited
21.3.2.1. Overview
21.3.2.2. Product Portfolio
21.3.2.3. Key Financials
21.3.2.4. SWOT Analysis
21.3.2.5. Sales Footprint
21.3.2.6. Strategy Overview
21.3.2.7. Key Developments
21.3.2.7.1. Marketing Strategies
21.3.2.7.2. Channel Strategies
21.3.3. Eli Lilly and Company
21.3.3.1. Overview
21.3.3.2. Product Portfolio
21.3.3.3. Key Financials
21.3.3.4. SWOT Analysis
21.3.3.5. Sales Footprint
21.3.3.6. Strategy Overview
21.3.3.7. Key Developments
21.3.3.7.1. Marketing Strategies
21.3.3.7.2. Channel Strategies
21.3.4. F. Hoffmann-La Roche Ltd.
21.3.4.1. Overview
21.3.4.2. Product Portfolio
21.3.4.3. Key Financials
21.3.4.4. SWOT Analysis
21.3.4.5. Sales Footprint
21.3.4.6. Strategy Overview
21.3.4.7. Key Developments
21.3.4.7.1. Marketing Strategies
21.3.4.7.2. Channel Strategies
21.3.5. Mylan N.V.
21.3.5.1. Overview
21.3.5.2. Product Portfolio
21.3.5.3. Key Financials
21.3.5.4. SWOT Analysis
21.3.5.5. Sales Footprint
21.3.5.6. Strategy Overview
21.3.5.7. Key Developments
21.3.5.7.1. Marketing Strategies
21.3.5.7.2. Channel Strategies
21.3.6. Teva Pharmaceutical Industries Ltd.
21.3.6.1. Overview
21.3.6.2. Product Portfolio
21.3.6.3. Key Financials
21.3.6.4. SWOT Analysis
21.3.6.5. Sales Footprint
21.3.6.6. Strategy Overview
21.3.6.7. Key Developments
21.3.6.7.1. Marketing Strategies
21.3.6.7.2. Channel Strategies
21.3.7. Sanofi
21.3.7.1. Overview
21.3.7.2. Product Portfolio
21.3.7.3. Key Financials
21.3.7.4. SWOT Analysis
21.3.7.5. Sales Footprint
21.3.7.6. Strategy Overview
21.3.7.7. Key Developments
21.3.7.7.1. Marketing Strategies
21.3.7.7.2. Channel Strategies
21.3.8. Novartis AG
21.3.8.1. Overview
21.3.8.2. Product Portfolio
21.3.8.3. Key Financials
21.3.8.4. SWOT Analysis
21.3.8.5. Sales Footprint
21.3.8.6. Strategy Overview
21.3.8.7. Key Developments
21.3.8.7.1. Marketing Strategies
21.3.8.7.2. Channel Strategies
21.3.9. Sun Pharmaceutical Industries Ltd.
21.3.9.1. Overview
21.3.9.2. Product Portfolio
21.3.9.3. Key Financials
21.3.9.4. SWOT Analysis
21.3.9.5. Sales Footprint
21.3.9.6. Strategy Overview
21.3.9.7. Key Developments
21.3.9.7.1. Marketing Strategies
21.3.9.7.2. Channel Strategies
21.3.10. Aurobindo Pharma
21.3.10.1. Overview
21.3.10.2. Product Portfolio
21.3.10.3. Key Financials
21.3.10.4. SWOT Analysis
21.3.10.5. Sales Footprint
21.3.10.6. Strategy Overview
21.3.10.7. Key Developments
21.3.10.7.1. Marketing Strategies
21.3.10.7.2. Channel Strategies
21.3.11. Lupin
21.3.11.1. Overview
21.3.11.2. Product Portfolio
21.3.11.3. Key Financials
21.3.11.4. SWOT Analysis
21.3.11.5. Sales Footprint
21.3.11.6. Strategy Overview
21.3.11.7. Key Developments
21.3.11.7.1. Marketing Strategies
21.3.11.7.2. Channel Strategies
21.3.12. Allergan
21.3.12.1. Overview
21.3.12.2. Product Portfolio
21.3.12.3. Key Financials
21.3.12.4. SWOT Analysis
21.3.12.5. Sales Footprint
21.3.12.6. Strategy Overview
21.3.12.7. Key Developments
21.3.12.7.1. Marketing Strategies
21.3.12.7.2. Channel Strategies
21.3.13. Merck & Co., Inc.
21.3.13.1. Overview
21.3.13.2. Product Portfolio
21.3.13.3. Key Financials
21.3.13.4. SWOT Analysis
21.3.13.5. Sales Footprint
21.3.13.6. Strategy Overview
21.3.13.7. Key Developments
21.3.13.7.1. Marketing Strategies
21.3.13.7.2. Channel Strategies
21.3.14. Pfizer Inc.
21.3.14.1. Overview
21.3.14.2. Product Portfolio
21.3.14.3. Key Financials
21.3.14.4. SWOT Analysis
21.3.14.5. Sales Footprint
21.3.14.6. Strategy Overview
21.3.14.7. Key Developments
21.3.14.7.1. Marketing Strategies
21.3.14.7.2. Channel Strategies
21.3.15. GlaxoSmithKline plc
21.3.15.1. Overview
21.3.15.2. Product Portfolio
21.3.15.3. Key Financials
21.3.15.4. SWOT Analysis
21.3.15.5. Sales Footprint
21.3.15.6. Strategy Overview
21.3.15.7. Key Developments
21.3.15.7.1. Marketing Strategies
21.3.15.7.2. Channel Strategies
21.3.16. Hikma Pharmaceuticals PLC
21.3.16.1. Overview
21.3.16.2. Product Portfolio
21.3.16.3. Key Financials
21.3.16.4. SWOT Analysis
21.3.16.5. Sales Footprint
21.3.16.6. Strategy Overview
21.3.16.7. Key Developments
21.3.16.7.1. Marketing Strategies
21.3.16.7.2. Channel Strategies
21.3.17. Cipla Inc.
21.3.17.1. Overview
21.3.17.2. Product Portfolio
21.3.17.3. Key Financials
21.3.17.4. SWOT Analysis
21.3.17.5. Sales Footprint
21.3.17.6. Strategy Overview
21.3.17.7. Key Developments
21.3.17.7.1. Marketing Strategies
21.3.17.7.2. Channel Strategies
21.3.18. Endo International plc
21.3.18.1. Overview
21.3.18.2. Product Portfolio
21.3.18.3. Key Financials
21.3.18.4. SWOT Analysis
21.3.18.5. Sales Footprint
21.3.18.6. Strategy Overview
21.3.18.7. Key Developments
21.3.18.7.1. Marketing Strategies
21.3.18.7.2. Channel Strategies
21.3.19. Otsuka Pharmaceutical Co., Ltd.
21.3.19.1. Overview
21.3.19.2. Product Portfolio
21.3.19.3. Key Financials
21.3.19.4. SWOT Analysis
21.3.19.5. Sales Footprint
21.3.19.6. Strategy Overview
21.3.19.7. Key Developments
21.3.19.7.1. Marketing Strategies
21.3.19.7.2. Channel Strategies
21.3.20. STI Pharma, LLC
21.3.20.1. Overview
21.3.20.2. Product Portfolio
21.3.20.3. Key Financials
21.3.20.4. SWOT Analysis
21.3.20.5. Sales Footprint
21.3.20.6. Strategy Overview
21.3.20.7. Key Developments
21.3.20.7.1. Marketing Strategies
21.3.20.7.2. Channel Strategies
22. Assumptions and Acronyms Used
23. Research Methodology
관련자료
